Benzamide

Benzamide

SCHEMBL867781

Cc1ccc(S(=O)(=O)O)cc1.NC(=O)c1ccccc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Benzamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 known ✓ P09874 2/20 0.55
CYP2D6 P10635 2/20 0.56
MAPK1 P28482 1/20 0.56
TDP1 Q9NUW8 3/20 0.55
RECQL P46063 2/20 0.55
TSHR P16473 2/20 0.55
MAPT P10636 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
POLB P06746 2/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C19 P33261 1/20 0.55
BLM P54132 1/20 0.55
PMP22 Q01453 1/20 0.55
HSD17B10 Q99714 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 6/20 0.49
TP53 P04637 1/20 0.49
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
LMNA P02545 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzamide SCHEMBL29998608 1.00 CYP2D6 (0.56) CYP2D6MAPK1TDP1RECQLTSHR
Benzamide SCHEMBL3944288 0.98 CYP2D6 (0.55) CYP2D6MAPK1TDP1RECQLTSHR
Benzamide SCHEMBL29958812 0.87 TSHR (0.67) CYP2D6TDP1RECQLTSHRMAPT
Benzamide SCHEMBL29958827 0.87 TSHR (0.67) CYP2D6TDP1RECQLTSHRMAPT
P-Toluenesulfonamide SCHEMBL7641434 0.86 CA2 (0.67) TDP1RECQLTSHRMAPTL3MBTL1
Benzoic Acid SCHEMBL9261231 0.86 SMN1; SMN2 (0.57) CYP2D6MAPK1TDP1RECQLTSHR
Benzil SCHEMBL2093919 0.86 CES2 (0.68) CYP2D6MAPK1TDP1RECQLTSHR
Benzamide SCHEMBL30128768 0.85 TSHR (0.64) CYP2D6TDP1RECQLTSHRMAPT
Benzamide SCHEMBL29958820 0.85 TSHR (0.64) CYP2D6TDP1RECQLTSHRMAPT
Benzamide SCHEMBL27614953 0.85 TSHR (0.64) CYP2D6TDP1RECQLTSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170313671-A1 NEW SALT OF ABEXINOSTAT, ASSOCIATED CRYSTALLINE FORM, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PHARMACYCLICS, INC. 2017-11-02 US disclosed
CN-105263917-A Novel salts of ABEXINOSTATE, related crystalline forms, processes for their preparation and pharmaceutical compositions containing them SERVIER LAB 2016-01-20 CN disclosed
US-8735415-B2 Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide NATCO PHARMA LIMITED (IN) 2014-05-27 US disclosed
CN-103012376-A Amide derivatives ASTRAZENECA AB 2013-04-03 CN disclosed
US-20120077833-A1 ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE NATCO PHARMA LIMITED (IN) 2012-03-29 US disclosed
US-20110190328-A1 ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE NATCO PHARMA LIMITED (IN) 2011-08-04 US disclosed
CN-1898216-A Amide derivatives ASTRAZENECA AB (SE) 2007-01-17 CN disclosed
EP-1667648-A2 COMPOSITIONS AND METHODS FOR TREATING BURNS Kohi Corporation (US) 2006-06-14 EP disclosed
WO-2005032470-A2 COMPOSITIONS AND METHODS FOR TREATING BURNS KOHI CORPORATION (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190328-A1 ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE SLC30A5, DNPEP, PAICS PARP1 733/4885CYP2D6 1379/4885MAPK1 2850/4885
US-20120077833-A1 ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE CA9, SLC30A5, SLC6A19 PARP1 1250/4885CYP2D6 1198/4885MAPK1 1586/4885
US-20170313671-A1 NEW SALT OF ABEXINOSTAT, ASSOCIATED CRYSTALLINE FORM, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HAX1, REN, CANX PARP1 1861/4885CYP2D6 779/4885MAPK1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.